GEORGIADIS PUSHES FOR A MORE COMPETITIVE EUROPE:Biotechnology at the Heart of the EU’s Future Health Strategy

Speaking at the EU Health Ministers’ Council in Luxembourg, Greece’s Health Minister called for less bureaucracy, stronger investment incentives, and faster patient access to innovation, arguing that Europe risks falling behind the United States, China, and India in the global biotechnology race.

Europe is facing one of the defining technological and economic challenges of the coming decade.

As the United States, China, and India continue to invest aggressively in biotechnology, artificial intelligence, and advanced healthcare innovation, the European Union is seeking ways to preserve its competitiveness and global leadership.

At the EU Health Ministers’ Council in Luxembourg, Greek Health Minister Adonis Georgiadis delivered a strong intervention on the proposed European Biotech Act, positioning biotechnology as a strategic pillar of Europe’s future economic and healthcare policy.

According to Georgiadis, Europe must move decisively if it wants to remain a global innovation powerhouse.

“Europe must become a place where innovative companies can grow, invest, and manufacture, while ensuring that patients benefit more rapidly from breakthrough technologies.”

Η δεύτερη παρέμβαση μου σήμερα στο Συμβούλιο Υπουργών Υγείας της ΕΕ στο Λουξεμβούργο για τον Ευρωπαϊκό Νόμο για την Βιοτεχνολογία. Η Ευρώπη πρέπει να γίνει περισσότερο ανταγωνιστική και λιγότερο γραφειοκρατική και να δώσει ισχυρά κίνητρα για να παράγεται καινοτομία εδώ. pic.twitter.com/EYCRpbc7e4

— Άδωνις Γεωργιάδης (@AdonisGeorgiadi) June 16, 2026

Biotechnology as a Strategic European Priority

The Greek minister argued that biotechnology is no longer merely a scientific field—it has become a strategic geopolitical and economic asset.

In his remarks, Georgiadis emphasized that Europe cannot afford to lose ground in the global race for innovation.

“Global competition is intense, and Europe cannot remain behind. The new legislation must help reverse the current trend that favors the United States, China, and India over Europe.”

His comments reflect growing concerns in Brussels that Europe is increasingly losing innovative biotech firms to markets that offer faster regulatory pathways, greater access to capital, and more favorable investment conditions.

Cutting Bureaucracy, Accelerating Innovation

A central theme of the Greek intervention was the need for regulatory simplification.

Georgiadis argued that the European Biotech Act must deliver tangible improvements by streamlining procedures and reducing administrative burdens that often delay innovation.

Greece proposed:

• Faster approval processes.
• Better coordination among Member States.
• Accelerated clinical trial procedures.
• More predictable regulatory frameworks.

“Regulatory simplification must deliver immediate results. Europe needs faster, more predictable, and better-coordinated procedures for clinical trials and product development.”

The proposal aligns closely with broader European discussions on reducing bureaucracy and enhancing industrial competitiveness across strategic sectors.

Addressing Europe’s Investment Gap

Another major issue highlighted by the Greek minister was financing.

While Europe continues to produce world-class scientific research, many innovative companies struggle to secure the funding necessary to scale operations and commercialize discoveries.

Georgiadis called for:

• Stronger late-stage financing mechanisms.
• Strategic investment initiatives.
• Pre-approved biomanufacturing infrastructure.
• Enhanced support for biosimilar medicines.

“Europe must address structural weaknesses in financing, scaling-up, and industrial development. Innovative companies should be able to remain and grow within Europe.”

The objective is to prevent European biotech champions from relocating abroad during critical stages of growth.

Strategic Projects for Europe’s Long-Term Competitiveness

Greece also emphasized that strategic biotechnology projects should focus on areas that provide tangible public value.

According to Georgiadis, priority should be given to technologies that:

• Address unmet medical needs.
• Strengthen supply chain resilience.
• Improve healthcare outcomes.
• Enhance Europe’s long-term competitiveness.

Such projects, he argued, should become central components of the new European biotechnology framework.

The Ultimate Benchmark: Patient Benefit

Perhaps the most important message of the Greek intervention concerned the role of patients.

Georgiadis stressed that the success of the European Biotech Act should not be measured solely by investment figures or industrial output.

Instead, success should ultimately be evaluated by its impact on citizens and healthcare systems.

“The real innovation is the innovation that reaches patients.”

He further argued that European citizens expect scientific breakthroughs to translate into practical healthcare benefits.

“Our citizens expect scientific achievements to become innovative medicines, advanced therapies, diagnostics, and better healthcare outcomes.”

This patient-centered approach places healthcare delivery at the core of Europe’s innovation strategy.

Greece’s Vision for European Health Policy

The intervention demonstrates Greece’s intention to play an active role in shaping the next generation of European health policy.

Athens is positioning itself as a supporter of:

• Scientific innovation.
• Advanced research.
• High-tech investment.
• Faster patient access to new therapies.
• A stronger European life sciences sector.

As healthcare increasingly intersects with industrial policy, competitiveness, and strategic autonomy, biotechnology is becoming one of the most important policy arenas in Brussels.

The debate surrounding the European Biotech Act goes far beyond healthcare.

It is fundamentally about Europe’s ability to compete in a rapidly changing global economy.

The European Union possesses world-class universities, research institutions, and scientific talent. The challenge is transforming that knowledge into commercial success, industrial capacity, and accessible healthcare innovation.

As Adonis Georgiadis concluded in Luxembourg:

“Europe has the talent, the science, and the ambition. The European Biotech Act must ensure that Europe has the capacity to transform innovation into better health for all Europeans.”

Whether Europe succeeds in that mission may determine not only the future of its biotechnology sector, but also its broader economic and strategic position in the decades ahead.

Source: pagenews.gr